Winstanley Erin L, Thacker Emily P, Choo Lyn Yuen, Lander Laura R, Berry James H, Tofighi Babak
Department of Behavioral Medicine and Psychiatry, School of Medicine and Rockefeller Neuroscience Institute, West Virginia University, Morgantown, WV, United States.
Department of Neuroscience, West Virginia University, Morgantown, WV, United States.
Drug Alcohol Depend Rep. 2022 Sep 8;5:100091. doi: 10.1016/j.dadr.2022.100091. eCollection 2022 Dec.
While barriers to accessing buprenorphine (BUP) therapy have been well described, little is known about pharmacy-related barriers. The objective of this study was to estimate the prevalence of patient-reported problems filling BUP prescriptions and determine whether these problems were associated with illicit use of BUP. The secondary objectives included identifying motivations for illicit BUP use and the prevalence of naloxone acquisition among patients prescribed BUP.
Between July 2019 and March 2020, 139 participants receiving treatment for an opioid use disorder (OUD) at two sites within a rurally-located health system, completed an anonymous 33-item survey. A multivariable model was used to assess the association between pharmacy-related problems filling BUP prescriptions and illicit substance use.
More than a third of participants reported having problems filling their BUP prescription (34.1%, = 47) with the most commonly reported problems being insufficient pharmacy stock of BUP (37.8%, = 17), pharmacist refusal to dispense BUP (37.8%, = 17), and insurance problems (34.0%, = 16). Of those who reported illicit BUP use (41.5%, = 56), the most common motivations were to avoid/ease withdrawal symptoms ( = 39), prevent/reduce cravings ( = 39), maintain abstinence ( = 30), and treat pain ( = 19). In the multivariable model, participants who reported a pharmacy-related problems were significantly more likely to use illicitly obtained BUP (OR=8.93, 95% CI: 3.12, 25.52, < 0.0001).
Efforts to improve BUP access have primarily focused on increasing the number of clinicians waivered to prescribe; however, challenges persist with BUP dispensing and coordinated efforts may be needed to systematically reduce pharmacy-related barriers.
虽然获取丁丙诺啡(BUP)治疗的障碍已得到充分描述,但对于与药房相关的障碍知之甚少。本研究的目的是估计患者报告的BUP处方配药问题的发生率,并确定这些问题是否与BUP的非法使用有关。次要目标包括确定非法使用BUP的动机以及开具BUP处方的患者中获取纳洛酮的发生率。
2019年7月至2020年3月期间,在一个农村卫生系统的两个地点接受阿片类物质使用障碍(OUD)治疗的139名参与者完成了一项33项的匿名调查。使用多变量模型评估BUP处方配药的药房相关问题与非法物质使用之间的关联。
超过三分之一的参与者报告在配药时遇到问题(34.1%,n = 47),最常报告的问题是药房BUP库存不足(37.8%,n = 17)、药剂师拒绝配发BUP(37.8%,n = 17)和保险问题(34.0%,n = 16)。在报告非法使用BUP的参与者中(41.5%,n = 56),最常见的动机是避免/缓解戒断症状(n = 39)、预防/减少渴望(n = 39)、维持禁欲(n = 30)和治疗疼痛(n = 19)。在多变量模型中,报告药房相关问题的参与者非法获取BUP的可能性显著更高(OR = 8.93,95% CI:3.12,25.52,P < 0.0001)。
改善BUP获取的努力主要集中在增加获得处方豁免的临床医生数量;然而,BUP配药方面的挑战仍然存在,可能需要协调各方努力以系统地减少与药房相关的障碍。